Navigation Links
Bioniche Pharma and Synerx Launch Isosulfan Blue Injection 1%
Date:7/28/2010

LAKE FOREST, Ill., July 28 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC announced today the FDA approval and launch of Isosulfan Blue Injection 1%.

(Photo:  http://photos.prnewswire.com/prnh/20100728/CG42156)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100728/CG42156)

(Logo:  http://photos.prnewswire.com/prnh/20080702/AQW070LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"Launching the first and only generic for Isosulfan Blue Injection 1% in the US reaffirms our commitment to introducing generic niche products, which allows hospitals and pharmacies an option in the buying process," said George Zorich, President, US Operations for Bioniche Pharma.

Isosulfan Blue Injection 1% will be supplied in a carton containing six 5mL (10 mg/mL)

single use vials.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, including anaesthesiology, orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma and prescribing information for its products can be found at www.bionichepharma.com.

About Synerx Pharma:

Synerx Pharma, LLC is a privately held corporation located in historic Bucks County Pennsylvania. Established in January 2004, the company develops and brings to market select pharmaceutical products aimed at addressing unmet market needs, particularly those involving some combination of barriers to entry. The company focuses on developing cost effective specialty generic pharmaceuticals and small brand products. Synerx presently has eight FDA approved products, of which five were First Time Generic Approvals, and a development portfolio of ten projects at various stages of development in multiple dosage forms. More information can be found at www.synerxpharma.com.

Lymphazurin™ is a trademark of Tyco Healthcare Group LP


'/>"/>
SOURCE Bioniche Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
2. RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc.
3. Bioniche Pharma Acquires Seven New Products From GeneraMedix Inc.
4. Bioniche Pharma Launches Ibutilide Fumarate Injection
5. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
6. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
9. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
10. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
11. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Cadence Design Systems, Inc. (NASDAQ: ... Tensilica ® Fusion F1 DSP is part of the ... The licensable IP targets SoCs designed for battery-powered sensor nodes ... leveraged the Fusion F1 DSP both to implement the IEEE ... trigger, audio identification and sensor fusion on a single DSP. ...
(Date:2/21/2017)... Research and Markets has announced the addition of the "Liver Cirrhosis ... ... Cirrhosis Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... answers the following questions: What are the key ... positioned in the Global Liver Cirrhosis market? What are ...
(Date:2/21/2017)... Research and Markets has announced the addition of ... to their offering. ... latest research Rosacea Drugs Price Analysis and Strategies - 2016, provides drug ... research answers the following questions: What are the ... positioned in the Global Rosacea market? What are the ...
Breaking Medicine Technology:
(Date:2/21/2017)... Atlanta, GA (PRWEB) , ... February 21, 2017 ... ... firm, announced the acquisition of the predictive analytic firm Predixion’s Healthcare IT practice. ... of investment and is backed by giants including Accenture, GE Ventures, ...
(Date:2/21/2017)... ... February 21, 2017 , ... Along with Valentine’s Day, ... and make small changes that can lead to a lifetime of heart health. ... a cardiac emergency. , The Athletic Trainers’ Society of New Jersey (ATSNJ) ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... Silverado today ... Healthcare to open and operate a state-of-the-art memory care community in Alexandria, Virginia. The ... on a site just outside of Old Town. , The three-story community with ...
(Date:2/20/2017)... ... 20, 2017 , ... The StayWell Company and VUCA Health ... patient health risks, foster behavior change and improve health literacy among patients. VUCA Health, ... a demonstration of its video capability at StayWell booth 3443 during HiMSS. , ...
(Date:2/20/2017)... ... February 20, 2017 , ... Houston dentist , Dr. ... care at his office, Antoine Dental Center. Emergency dentistry encompasses many treatments for ... at risk for serious complications and often experience severe pain. Not only does ...
Breaking Medicine News(10 mins):